News Forum

Roche net profit up 34 pct on cancer drug sales

 
 



Go Back   News Forum > General Discussion Forums > Business
Business Forum Roche net profit up 34 pct on cancer drug sales at News Forum - Reuters - Net profit at Roche Holding AG rose 34 percent to 9.17 billion Swiss francs ($7.33 billion) in 2006 ...

Reply
 
LinkBack Thread Tools Display Modes
Old 02-07-2007, 04:25 AM   #1
Senior Member
 
NF Reporter's Avatar
 
Join Date: Nov 2006
Posts: 67,440
Default Roche net profit up 34 pct on cancer drug sales

Reuters - Net profit at Roche Holding AG rose 34 percent to 9.17 billion Swiss francs ($7.33 billion) in 2006 due to strong sales of cancer treatments Herceptin and Avastin, just ahead of analysts' expectations.

Full Story...
NF Reporter is offline  
Digg this Post!Add Post to del.icio.usBookmark Post in TechnoratiFurl this Post!
Reply With Quote
Old 11-18-2007, 10:40 PM   #2
Senior Member
 
Join Date: Aug 2007
Location: Okolona, Ky.
Posts: 26,337
Lightbulb

May be able to use Avastin for brain cancer...

Avastin shows promise for deadly brain cancer
Nov 18, 2007 - -- Genentech, Inc. announced today that a better than expected percentage of patients with relapsed glioblastoma multiforme (GBM) the most common and aggressive brain cancer remained free of progression for six months when they used Avastin (or bevascizumab) alone or in combination with irinotecan chemotherapy.
Quote:
The randomized, multi-center Phase II clinical trial reported at the 12th Annual Scientific Meeting of the Society for Neuro-Oncology showed "36 percent (31/85) of GBM patients treated with Avastin alone, and 51 percent (42/82) of patients treated with Avastin in combination with chemotherapy, lived without the disease advancing within six months," Genentech said in its press release. "Historical estimates suggest that only 15 percent of patients with this aggressive type of brain cancer live without their cancer progressing within six months," said Timothy Cloughesy, M.D., director, Neuro-Oncology Program of the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles and lead investigator for the study.

"The findings suggested that at six months, more patients had lived without their cancer advancing when Avastin was administered as a single-agent or in combination with chemotherapy, than what we would normally expect. "These findings exceeded our expectations, and due to the high unmet medical need of patients with relapsed GBM we plan to discuss these data with the FDA to determine next steps," said

Based on the results and the high medical need of patients with the brain cancer, the company plans to discuss these data with the FDA to determine next steps, said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. In the United State an estimated 20,500 new cases of brain cancer are diagnosed each year and 12,740 patients will die from the disease, according to the American Cancer Society. The five-year survival rate for patients with GBW is only 3 %.

MORE
waltky is offline  
Digg this Post!Add Post to del.icio.usBookmark Post in TechnoratiFurl this Post!
Reply With Quote
Reply


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On


Similar Threads
Thread Thread Starter Forum Replies Last Post
Biogen quarterly profit rises on higher drug sales NF Reporter Business 0 02-15-2007 08:40 AM
J&J quarterly profit rises on higher drug sales NF Reporter Business 0 01-23-2007 09:46 AM
Lucentis,cancer drugs lift Genentech profit NF Reporter Business 0 01-10-2007 10:17 PM
Lucentis, cancer drugs lift Genentech profit NF Reporter Business 0 01-10-2007 06:46 PM
Adobe profit rises on higher software sales NF Reporter Business 2 12-16-2006 06:22 PM


All times are GMT -5. The time now is 08:50 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2017, vBulletin Solutions, Inc.

SEO by vBSEO 3.2.0 ©2008, Crawlability, Inc.